© 2005 Oxford University Press
ARTICLE |
Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene
Affiliations of authors: Department of Medicine and Ireland Comprehensive Cancer Center, Case Western Reserve University, and University Hospitals of Cleveland, Cleveland, OH (W-DC, JS, LM, PP, SL, JKVW); Exact Sciences, Marlborough, MA (JS, ZJH, JO, AS); Department of Pathology and Ireland Comprehensive Cancer Center, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH (DD, JW, TPP); Department of Epidemiology and Biostatistics and Ireland Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH (JSR); Department of Medicine and Ireland Comprehensive Cancer Center, Case Western Reserve University and University Hospitals of Cleveland, and Howard Hughes Medical Institute, Cleveland, OH (JL, LK, SDM)
Correspondence to: Sanford Markowitz, MD, PhD, Case Western Reserve University, WRB 3-127, 10900 Euclid Ave., Cleveland, OH 44106-7285 (e-mail: sxm10{at}cwru.edu).
Background: Increased DNA methylation is an epigenetic alteration that is common in human cancers and is often associated with transcriptional silencing. Aberrantly methylated DNA has also been proposed as a potential tumor marker. However, genes such as vimentin, which are transcriptionally silent in normal epithelium, have not until now been considered as targets for cancer-associated aberrant methylation and for use as cancer markers. Methods: We applied methylation-specific polymerase chain reaction to the vimentin gene, which is transcriptionally silent in normal colonocytes, and compared methylation of vimentin exon 1 in cancer tissues and in fecal DNA from colon cancer patients versus control samples from healthy subjects. Results: Vimentin exon-1 sequences were unmethylated in 45 of 46 normal colon tissues. In contrast, vimentin exon-1 sequences were methylated in 83% (38 of 46) and 53% (57 of 107) of tumors from two independently collected groups of colon cancer patients. When evaluated as a marker for colon cancer detection in fecal DNA from another set of colon cancer patients, aberrant vimentin methylation was detected in fecal DNA from 43 of 94 patients, for a sensitivity of 46% (95% confidence interval [CI] = 35% to 56%). The sensitivity for detecting stage I and II cancers was 43% (26 of 60 case patients) (95% CI = 31% to 57%). Only 10% (20 of 198 case patients) of control fecal DNA samples from cancer-free individuals tested positive for vimentin methylation, for a specificity of 90% (95% CI = 85% to 94%). Conclusions: Aberrant methylation of exon-1 sequences within the nontranscribed vimentin gene is a novel molecular biomarker of colon cancer and can be successfully detected in fecal DNA to identify nearly half of individuals with colon cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Fecal DNA Biomarkers for the Detection of Colorectal Neoplasia: Attractive, but Is It Feasible?
- Dean E. Brenner and Gad Rennert
J Natl Cancer Inst 2005 97: 1107-1109.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  T. Nagasaka, N. Tanaka, H. M. Cullings, D.-S. Sun, H. Sasamoto, T. Uchida, M. Koi, N. Nishida, Y. Naomoto, C. R. Boland, et al. Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia J Natl Cancer Inst, September 16, 2009; 101(18): 1244 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Itzkowitz Incremental Advances in Excremental Cancer Detection Tests J Natl Cancer Inst, September 16, 2009; 101(18): 1225 - 1227. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ausch, Y.-H. Kim, K. D. Tsuchiya, S. Dzieciatkowski, M. K. Washington, C. Paraskeva, J. Radich, and W. M. Grady Comparative Analysis of PCR-Based Biomarker Assay Methods for Colorectal Polyp Detection from Fecal DNA Clin. Chem., August 1, 2009; 55(8): 1559 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Melotte, M. H. F. M. Lentjes, S. M. van den Bosch, D. M. E. I. Hellebrekers, J. P. J. de Hoon, K. A. D. Wouters, K. L. J. Daenen, I. E. J. M. Partouns-Hendriks, F. Stessels, J. Louwagie, et al. N-Myc Downstream-Regulated Gene 4 (NDRG4): A Candidate Tumor Suppressor Gene and Potential Biomarker for Colorectal Cancer J Natl Cancer Inst, July 1, 2009; 101(13): 916 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rennert Are We Getting Closer to Molecular Population Screening for Colorectal Cancer? J Natl Cancer Inst, July 1, 2009; 101(13): 902 - 903. [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. McCabe, J. C. Brandes, and P. M. Vertino Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3927 - 3937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M.E.I. Hellebrekers, M. H.F.M. Lentjes, S. M. van den Bosch, V. Melotte, K. A.D. Wouters, K. L.J. Daenen, K. M. Smits, Y. Akiyama, Y. Yuasa, S. Sanduleanu, et al. GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3990 - 3997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Markowitz, S. H. Itzkowitz, and B. M. Berger The Effectiveness of Colonoscopy in Reducing Mortality From Colorectal Cancer Ann Intern Med, June 2, 2009; 150(11): 816 - 817. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takai, S. Kanaoka, K.-i. Yoshida, Y. Hamaya, M. Ikuma, N. Miura, H. Sugimura, M. Kajimura, and A. Hishida Fecal Cyclooxygenase 2 Plus Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal Cancer Screening Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1888 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. KITAMURA, A. SHIRAHATA, M. SAKATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, et al. Frequent Methylation of Vimentin in Well-differentiated Gastric Carcinoma Anticancer Res, June 1, 2009; 29(6): 2227 - 2229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, et al. Methylation of HACE1 in Gastric Carcinoma Anticancer Res, June 1, 2009; 29(6): 2231 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Glockner, M. Dhir, J. M. Yi, K. E. McGarvey, L. Van Neste, J. Louwagie, T. A. Chan, W. Kleeberger, A. P. de Bruine, K. M. Smits, et al. Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer Cancer Res., June 1, 2009; 69(11): 4691 - 4699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhao, I. Ivanov, E. R. Dougherty, T. J. Hartman, E. Lanza, G. Bobe, N. H. Colburn, J. R. Lupton, L. A. Davidson, and R. S. Chapkin Noninvasive Detection of Candidate Molecular Biomarkers in Subjects with a History of Insulin Resistance and Colorectal Adenomas Cancer Prevention Research, June 1, 2009; 2(6): 590 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Graser, P Stieber, D Nagel, C Schafer, D Horst, C R Becker, K Nikolaou, A Lottes, S Geisbusch, H Kramer, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population Gut, February 1, 2009; 58(2): 241 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Koga, M. Yasunaga, Y. Moriya, T. Akasu, S. Fujita, S. Yamamoto, H. Baba, and Y. Matsumura Detection of the DNA Point Mutation of Colorectal Cancer Cells Isolated from Feces Stored Under Different Conditions Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. SHIRAHATA, M. SAKATA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, et al. Vimentin Methylation as a Marker for Advanced Colorectal Carcinoma Anticancer Res, January 1, 2009; 29(1): 279 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Ahlquist, D. J. Sargent, C. L. Loprinzi, T. R. Levin, D. K. Rex, D. J. Ahnen, K. Knigge, M. P. Lance, L. J. Burgart, S. R. Hamilton, et al. Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia Ann Intern Med, October 7, 2008; 149(7): 441 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Chung Stool DNA Testing and Colon Cancer Prevention: Another Step Forward Ann Intern Med, October 7, 2008; 149(7): 509 - 510. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ito, T. Koessler, A. E.K. Ibrahim, S. Rai, S. L. Vowler, S. Abu-Amero, A.-L. Silva, A.-T. Maia, J. E. Huddleston, S. Uribe-Lewis, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer Hum. Mol. Genet., September 1, 2008; 17(17): 2633 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zou, J. J. Harrington, A. M. Shire, R. L. Rego, L. Wang, M. E. Campbell, A. L. Oberg, and D. A. Ahlquist Highly Methylated Genes in Colorectal Neoplasia: Implications for Screening Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2686 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zou, J. Harrington, R. L. Rego, and D. A. Ahlquist A Novel Method to Capture Methylated Human DNA from Stool: Implications for Colorectal Cancer Screening Clin. Chem., September 1, 2007; 53(9): 1646 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhao, Y. Xiao, P. Elson, H. Tan, S. J. Plummer, M. Berk, P. P. Aung, I. C. Lavery, J. P. Achkar, L. Li, et al. Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2696 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Model, N. Osborn, D. Ahlquist, R. Gruetzmann, B. Molnar, F. Sipos, O. Galamb, C. Pilarsky, H.-D. Saeger, Z. Tulassay, et al. Identification and Validation of Colorectal Neoplasia-Specific Methylation Markers for Accurate Classification of Disease Mol. Cancer Res., February 1, 2007; 5(2): 153 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Levin Molecular Screening Testing for Colorectal Cancer Clin. Cancer Res., September 1, 2006; 12(17): 5014 - 5017. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Brenner and G. Rennert Fecal DNA Biomarkers for the Detection of Colorectal Neoplasia: Attractive, but Is It Feasible? J Natl Cancer Inst, August 3, 2005; 97(15): 1107 - 1109. [Full Text] [PDF]
|
|